MedPacto, Inc. (235980.KQ) KOE
3,465.00
+35(+1.02%)
Currency In KRW
- General
- Statistics
- Historical Data
- Profile
- Financials
3,465.00
+35(+1.02%)
Currency In KRW
Address
Borim Building
Seoul, 06668
Korea (the Republic of)
Phone
82 2 6938 0200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
56
First IPO Date
December 19, 2019
| Name | Title | Pay | Year Born |
| Seong-Jin Kim | Founder & Chief Executive Officer | 0 | N/A |
| Ki Baik Hahm | Executive Vice President of R&D | 0 | N/A |
| Timothy R. Allen | Executive Vice President of Clinical Development at MedPacto Therapeutics - U.S. | 0 | N/A |
| Sunjin Hwang | Chief Medical Officer | 0 | N/A |
| Jungwon Woo | President | 0 | N/A |
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.